Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FRACTYL HEALTH, INC.GUTS · Entity 6700 | Chief Scientific Officer | February 27, 2025 | March 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FRACTYL HEALTH, INC.
Report date February 27, 2025 · Filed March 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.46 · Expires 2035-02-26 | Direct | 169,700 |
Reported balance
After 2025-02-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-02-27 · Grant · Acquired 169,700 · Balance 169,700 F1: The stock option vests and becomes exercisable in equal installments on each of the first four anniversaries of the grant date, subject to the Reporting Persons's continuing in employment through each such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2034-01-31 | Direct | 35,280 |
Reported balance
After 2025-02-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-02-27 · Grant · Acquired 35,280 · Balance 35,280 F2: In connection with the Issuer's initial public offering, on February 1, 2024 the Reporting Person was granted, subject to the satisfaction of certain performance criteria, an option to purchase 58,800 shares of common stock to vest in the form of shares of the Issuer's common stock in four substantially equal installments on December 31, 2024 and each of the first three anniversaries thereof. On February 27, 2025, the Issuer's administrator determined that the performance criteria were partially met, resulting in 35,280 shares subject to such option being earned, of which 25% vested on December 31, 2024 and the remaining 75% will vest in substantially equal installments on the first three anniversaries thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable in equal installments on each of the first four anniversaries of the grant date, subject to the Reporting Persons's continuing in employment through each such vesting date.
F2: In connection with the Issuer's initial public offering, on February 1, 2024 the Reporting Person was granted, subject to the satisfaction of certain performance criteria, an option to purchase 58,800 shares of common stock to vest in the form of shares of the Issuer's common stock in four substantially equal installments on December 31, 2024 and each of the first three anniversaries thereof. On February 27, 2025, the Issuer's administrator determined that the performance criteria were partially met, resulting in 35,280 shares subject to such option being earned, of which 25% vested on December 31, 2024 and the remaining 75% will vest in substantially equal installments on the first three anniversaries thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2025 Filed Mar 3, 2025 21:02 UTC | FRACTYL HEALTH, INC. GUTS · Entity 6700 | GrantStock Option (right to buy) · Derivative | 35,280 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0000950170-25-031269 · ownership.xml · derivative · entry 2 Kieffer Timothy · CIK 0002004011 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,280 Underlying: Common Stock · 35,280 shares Expires 2034-01-31 F2 · derivative.exercise_date: In connection with the Issuer's initial public offering, on February 1, 2024 the Reporting Person was granted, subject to the satisfaction of certain performance criteria, an option to purchase 58,800 shares of common stock to vest in the form of shares of the Issuer's common stock in four substantially equal installments on December 31, 2024 and each of the first three anniversaries thereof. On February 27, 2025, the Issuer's administrator determined that the performance criteria were partially met, resulting in 35,280 shares subject to such option being earned, of which 25% vested on December 31, 2024 and the remaining 75% will vest in substantially equal installments on the first three anniversaries thereof. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:02 UTC | FRACTYL HEALTH, INC. GUTS · Entity 6700 | GrantStock Option (right to buy) · Derivative | 169,700 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0000950170-25-031269 · ownership.xml · derivative · entry 1 Kieffer Timothy · CIK 0002004011 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,700 Underlying: Common Stock · 169,700 shares Expires 2035-02-26 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in equal installments on each of the first four anniversaries of the grant date, subject to the Reporting Persons's continuing in employment through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.